VT-122: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=VT-122 (Propranolol and Etodolac combination) |FDA_approval=No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions) |used_for=Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma |clinical_trial_phase=Phase 2 (based on ongoing and completed trials for various cancer t...") |
No edit summary |
||
| Line 8: | Line 8: | ||
|OS_with=In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122 | |OS_with=In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122 | ||
|PFS_with=Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies | |PFS_with=Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies | ||
|usefulness_rating= | |usefulness_rating=4 | ||
|notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile. | |notes=VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile. | ||
|category=Repurposed Drugs | |category=Repurposed Drugs | ||
|links= | |links= | ||
}} | }} | ||
Revision as of 06:34, 24 March 2024
| Property | Information |
|---|---|
| Drug Name | VT-122 (Propranolol and Etodolac combination) |
| Overview | |
| FDA Approval | No (VT-122 is an investigational combination of repurposed drugs; Propranolol and Etodolac are FDA-approved for other conditions) |
| Used for | Investigational use in cancer treatment, specifically targeting cachexia in non-small cell lung cancer, hepatocellular carcinoma, and potentially glioblastoma |
| Clinical Trial Phase | Phase 2 (based on ongoing and completed trials for various cancer types) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Higher rates of thrombocytopenia, neutropenia, and anemia were observed in some studies |
| OS without | In the glioblastoma study, median overall survival was 9.2 months with low-dose TMZ alone |
| OS with | In the same glioblastoma study, median overall survival was 17.6 months with low-dose TMZ + VT-122 |
| PFS without | Not specified |
| PFS with | Not specified; efficacy primarily reported in terms of overall survival and response rates in available studies |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: VT-122, combining Propranolol and Etodolac, is under investigation for its potential to enhance survival and reduce cachexia in cancer patients. Preliminary results in glioblastoma suggest a notable improvement in overall survival and response rates when combined with low-dose temozolomide, indicating a promising direction for further research. The study's outcomes, including high response rates and an extended median survival time, highlight VT-122's potential, albeit with the need for more comprehensive trials to fully ascertain its benefits and safety profile.
From Ben Williams Book: Not specified
Loading comments...
